1. Home
  2. ONC vs HUM Comparison

ONC vs HUM Comparison

Compare ONC & HUM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • HUM
  • Stock Information
  • Founded
  • ONC 2010
  • HUM 1961
  • Country
  • ONC Switzerland
  • HUM United States
  • Employees
  • ONC N/A
  • HUM N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • HUM Medical Specialities
  • Sector
  • ONC Health Care
  • HUM Health Care
  • Exchange
  • ONC Nasdaq
  • HUM Nasdaq
  • Market Cap
  • ONC 26.9B
  • HUM 28.2B
  • IPO Year
  • ONC N/A
  • HUM 1993
  • Fundamental
  • Price
  • ONC $247.08
  • HUM $239.66
  • Analyst Decision
  • ONC Strong Buy
  • HUM Hold
  • Analyst Count
  • ONC 7
  • HUM 21
  • Target Price
  • ONC $326.43
  • HUM $279.05
  • AVG Volume (30 Days)
  • ONC 314.8K
  • HUM 1.7M
  • Earning Date
  • ONC 08-06-2025
  • HUM 07-30-2025
  • Dividend Yield
  • ONC N/A
  • HUM 1.48%
  • EPS Growth
  • ONC N/A
  • HUM N/A
  • EPS
  • ONC N/A
  • HUM 14.16
  • Revenue
  • ONC $4,175,868,000.00
  • HUM $120,262,000,000.00
  • Revenue This Year
  • ONC $869.15
  • HUM $8.72
  • Revenue Next Year
  • ONC $19.07
  • HUM $2.81
  • P/E Ratio
  • ONC N/A
  • HUM $16.92
  • Revenue Growth
  • ONC 51.16
  • HUM 10.09
  • 52 Week Low
  • ONC $141.31
  • HUM $212.45
  • 52 Week High
  • ONC $287.88
  • HUM $406.46
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • HUM 51.26
  • Support Level
  • ONC N/A
  • HUM $229.23
  • Resistance Level
  • ONC N/A
  • HUM $237.82
  • Average True Range (ATR)
  • ONC 0.00
  • HUM 6.73
  • MACD
  • ONC 0.00
  • HUM 2.25
  • Stochastic Oscillator
  • ONC 0.00
  • HUM 67.20

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About HUM Humana Inc.

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Share on Social Networks: